Torri McPherson
Family · Bay City, MINPI 1770364804
Payments from drug & device makers
Across 95 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$369
- AstraZeneca$260
- Axsome Therapeutics, Inc.$138
- Otsuka America Pharmaceutical, Inc.$129
- GSK$128
- Lilly USA, LLC$125
- plus $789 from 17 others
What the payments were for
- Food & beverage$1,939100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $369 |
| AstraZeneca | 12 | $260 |
| Axsome Therapeutics, Inc. | 6 | $138 |
| Otsuka America Pharmaceutical, Inc. | 5 | $129 |
| GSK | 7 | $128 |
| Lilly USA, LLC | 8 | $125 |
| Astellas Pharma US Inc | 5 | $107 |
| Vanda Pharmaceuticals Inc. | 4 | $105 |
| Amgen | 5 | $99 |
| Pfizer | 5 | $96 |
| Lundbeck LLC | 3 | $53 |
| Exact Sciences | 2 | $44 |
| Merck | 2 | $41 |
| Corcept Therapeutics | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Averitas Pharma Inc. | 1 | $20 |
| Pulmonx Corporation | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Cipher Pharmaceuticals US LLC | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
How this compares
$1,939 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 35 | $38,052 |
| EliquisApixaban | 49 | $17,325 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $11,526 |
| JardianceEmpagliflozin | 37 | $10,447 |
| EntrestoSacubitril/Valsartan | 11 | $3,227 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $2,481 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 122 | $1,782 |
| Gabapentin | 124 | $1,633 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,332 |
| Atorvastatin Calcium | 88 | $1,041 |
| Sertraline Hcl | 65 | $991 |
| Fentanyl | 15 | $973 |
| Ondansetron Hcl | 19 | $878 |
| Midodrine Hcl | 21 | $753 |
| Levothyroxine Sodium | 62 | $693 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $125 | $38,05235 claims |
| PfizerEliquis | $96 | $17,32549 claims |
| GSKTrelegy Ellipta | $128 | $11,52615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.
Other family in Bay City
- Tracy RobertsonBay City$47K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.